Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02077959 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02077959: Clinical Trial Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT02077959 is a Phase 1 study that was terminated before completion, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02077959, a Phase 1 study, was terminated before completion, sponsored by Ohio State University Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of lenalidomide and pidilizumab and to see how well they work in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as pidilizumab, can block cancer growth by blocking the ability of cancer to grow and spread. Giving lenalidomide with pidilizumab may work better in treating relapsed or refractory multiple myeloma.
Interventions
- OTHER laboratory biomarker analysis
- DRUG lenalidomide
- OTHER pharmacological study
- BIOLOGICAL pidilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-03-03 |
| Est. Completion | 2019-05-24 |
| Phase | Phase 1 |
Why NCT02077959 stopped before completion
NCT02077959 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02077959 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02077959 about?
NCT02077959 is a clinical study titled "Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma". This phase I/II trial studies the side effects and best dose of lenalidomide and pidilizumab and to see how well they work in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment (refractory). Biological therapies, such as lenalidomide, may stimulat...
What is the current status of trial NCT02077959?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-03-03. Estimated completion is 2019-05-24.
What interventions are being tested in trial NCT02077959?
The interventions under investigation include: laboratory biomarker analysis (OTHER), lenalidomide (DRUG), pharmacological study (OTHER), pidilizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02077959?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02077959's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI